Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
FDC Limited is an Indian pharmaceutical company focused on branded generic formulations across therapeutic areas including gastroenterology, dermatology, ophthalmology, and vitamins/nutraceuticals. The company operates primarily in the domestic Indian market with growing international presence, competing on brand equity and distribution reach rather than pure API manufacturing. Recent margin compression despite revenue growth suggests pricing pressure or input cost inflation in a competitive generic drug environment.
FDC generates revenue by marketing branded generic drugs through a field force of medical representatives targeting physicians and pharmacies. Unlike pure generic players competing on price, FDC builds brand equity in therapeutic niches where physician preference and patient loyalty create modest pricing power. The company sources APIs domestically and internationally, formulates finished dosages, and distributes through a multi-tier pharmacy network. Gross margins of 39.6% reflect formulation value-add but are compressed versus pure-play branded pharma due to generic competition. Operating leverage is moderate given fixed costs in sales force, manufacturing facilities, and regulatory compliance.
Domestic pharmaceutical market growth rates in India (volume-driven prescription trends)
API and raw material cost inflation, particularly for imported ingredients sensitive to USD/INR exchange rates
Regulatory actions by Indian drug authorities affecting product approvals or pricing caps
Market share gains/losses in key therapeutic segments versus competitors like Sun Pharma, Cipla, Dr. Reddy's
International market penetration success, particularly in regulated markets requiring USFDA/EUGMP approvals
Indian government price control policies (National Pharmaceutical Pricing Authority caps on essential medicines) limiting pricing power and margin expansion
Increasing regulatory scrutiny on drug quality and manufacturing standards requiring continuous capex for compliance
Shift toward biosimilars and specialty drugs where FDC has limited presence, potentially eroding market share in traditional small-molecule generics
Intense competition from larger Indian pharma players (Sun Pharma, Cipla, Lupin) with greater R&D budgets and international scale
Entry of multinational pharma companies into Indian branded generics market leveraging global portfolios
Consolidation among distributors and pharmacy chains increasing buyer power and compressing distributor margins
Minimal financial leverage risk given 0.01 D/E ratio, but high current ratio suggests potential inefficiency in working capital deployment
Declining ROE (9.3%) and negative earnings growth (-12.6%) indicate potential asset productivity issues or one-time charges requiring investigation
low-to-moderate - Pharmaceutical demand is relatively inelastic as healthcare is non-discretionary, but branded generics face volume pressure during economic downturns when patients trade down to cheaper alternatives. Indian GDP growth drives middle-class expansion and healthcare spending, supporting prescription volume growth. However, government price controls and insurance reimbursement pressures can offset cyclical tailwinds.
Low direct sensitivity given minimal debt (0.01 D/E ratio) means negligible financing cost exposure. However, rising rates in India (influenced by US Federal Funds Rate through capital flows) can strengthen the rupee, reducing import costs for APIs but also compressing export competitiveness. Valuation multiples contract when rates rise as investors demand higher equity risk premiums.
Minimal - The company operates with negligible leverage and strong liquidity (2.98x current ratio). Credit conditions affect working capital financing costs marginally and customer payment terms in international markets, but overall impact is limited given the balance sheet strength.
value - Trading at 3.0x P/S and 2.5x P/B with 4.3% FCF yield suggests value orientation, particularly given negative recent returns (-20.3% over 6 months). The stock appeals to investors seeking exposure to India's healthcare growth story at reasonable valuations, but recent earnings decline and margin compression have deterred growth investors. Dividend profile unclear from provided data but typical for Indian pharma value plays.
moderate-to-high - Emerging market pharma stocks exhibit elevated volatility due to regulatory unpredictability, currency fluctuations, and episodic quality/compliance issues. Recent 6-month drawdown of -20.3% versus -6.3% over 1-year indicates event-driven volatility, likely related to earnings disappointment or sector-specific concerns.
